Your session is about to expire
← Back to Search
Durvalumab vs Chemotherapy for Non-Small Cell Lung Cancer
Study Summary
This trial is testing a new cancer drug against standard chemotherapy to see if it is more effective and has less side effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am fully active or restricted in physically strenuous activity but can do light work.I have stable brain or spinal metastases and haven't taken steroids for 14 days.I have or had an autoimmune or inflammatory disorder like colitis.I have not had chemotherapy or any systemic therapy for advanced NSCLC.My cancer shows high PD-L1 expression.I am 18 years old or older.My condition is Stage IV non-small cell lung cancer.My cancer does not have EGFR mutations or ALK rearrangements.My lung cancer is a mix of small-cell and non-small cell types.I have previously received immunotherapy but not cancer vaccines.
- Group 1: Arm 1: Durvalumab
- Group 2: Arm 2: Standard of Care
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this study hope to include patients who are elderly?
"The current recruitment effort is focused on patients that are between 18 and 130 years old."
Is this study actively looking for participants?
"Unfortunately, this particular clinical trial is not presently looking for candidates. The study was initially posted on 1/2/2017 and updated for the last time on 10/19/2022. However, if you are exploring other studies, there are currently 1559 trials actively recruiting patients with non-small cell lung carcinoma (nsclc) and 1916 studies for Durvalumab (MEDI4736) enrolling participants."
Might there be any adverse effects to treatment with Durvalumab (MEDI4736)?
"There is both preclinical and clinical evidence to support the safety of Durvalumab (MEDI4736), which our team has rated as a 3."
Could I take part in this experiment if I wanted to?
"The ideal candidate for this clinical trial would have non-small cell lung carcinoma (nsclc), and be between 18-130 years old. Currently, the team is looking to recruit 671 patients in total."
For what purpose is Durvalumab (MEDI4736) often utilized?
"Durvalumab (MEDI4736) can be used to treat cancer in the fallopian tubes, as well as other diseases and conditions."
How many people can join this clinical trial at its maximum enrollment?
"Unfortunately, this particular study is no longer looking for participants. The trial was posted on January 2nd, 2017 and last updated on October 19th, 2022. However, there are many other studies which may be of interest; 1559 trials for non-small cell lung carcinoma (nsclc) and 1916 involving Durvalumab (MEDI4736) are currently ongoing and actively recruiting patients."
Share this study with friends
Copy Link
Messenger